LivaNova Agrees to Acquire TandemLife


February 14, 2018—LivaNova PLC announced it has entered into an agreement to acquire TandemLife. TandemLife offers four product systems built around a common pump and controller that include extracorporeal life support (ECLS) and percutaneous mechanical circulatory support (pMCS) systems.

According to LivaNova, the acquisition of TandemLife’s complete portfolio of advanced cardiopulmonary support products will help to enhance the company’s cardiac surgery offerings.

“Use of ECLS and pMCS systems is on the rise, and technologic advancements have made products easier to use and more efficacious, leading to growth in the number of hospitals capable of performing these advanced procedures,” said Damien McDonald, LivaNova’s Chief Executive Officer.

LivaNova has agreed to pay up to $250 million for TandemLife, with upfront costs totaling about $200 million and up to an additional $50 million in contingent considerations based on regulatory milestones, stated LivaNova in their announcement.

The acquisition is expected to close in the first half of 2018, subject to approvals and other customary closing conditions.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.